Drug intelligence / Profile preview

GPCR 4 program

Development stage: Preclinical
Lead developer: Superluminal Medicines
Modality: Small Molecules

Overview

GPCR 4 is a preclinical small molecule antagonist targeting an undisclosed G protein-coupled receptor (GPCR), developed by Superluminal Medicines. The program is currently in the Hit Identification (Hit ID) stage. Superluminal Medicines utilizes a generative biology platform that integrates structural biology, machine learning, and proprietary assays to design highly selective small molecules. This program is part of a broader pipeline focused on addressing endocrine and cardiometabolic diseases, aiming to create candidate-ready compounds for targets that have historically been difficult to drug.

Targets

MC4R (Melanocortin 4 receptor)

Beyond the preview

Go deeper on GPCR 4 program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPCR 4 program.

Explore the full profile